Methods and compositions for treating cardiovascular diseases using fat specific protein 27 (fsp27) compositions

Abstract

FSP27 compositions and methods for treating cardiovascular diseases are described.

1 . A method for inhibiting cardiovascular disease in a subject, comprising,
 administering an FSP27 medicament or a pharmaceutically acceptable composition thereof, in an amount to treat cardiovascular disease.   
     
     
         2 . The method according to  claim 1 , wherein the cardiovascular disease is selected from one or more of the following: cardiovascular conditions: ischemic heart disease, coronary artery disease (CAD), angina, infarction, coronary syndrome, peripheral artery disease (PAD), cerebrovascular disease, stroke, congestive heart failure, systolic or diastolic cardiomyopathy, insulin resistance, vascular spasm, vasospastic angina, cardiac arrhythmia, impaired angiogenesis, reduced vascular growth. 
     
     
         3 . The method of  claim 1 , wherein the FSP27 medicament comprises full length FSP27 [SEQ ID NO: 12], or peptide fragments thereof. 
     
     
         4 . The method of  claim 3 , wherein the FSP27 fragment is one or more of SEQ ID NOS: 1-11, or variants or isoforms thereof. 
     
     
         5 . The method of  claim 3 , wherein the FSP27 fragment comprises Cf4, having SEQ ID NO:4. 
     
     
         6 . The method of  claim 1 , wherein the FSP27 medicament is co-administered with at least one additional therapeutic agent. 
     
     
         7 . A method of treating cardiovascular disease in a subject, the method comprising:
 administering a composition comprising a nucleic acid encoding a FSP27 protein to a subject;   wherein the FSP27 protein has an amino acid sequence having greater than about 85% homology to at least one of the FSP27 sequences shown in  FIG. 16  or fragments shown in Table 1 in  FIG. 17 .   
     
     
         8 . (canceled) 
     
     
         9 . An FSP27 medicament, or a pharmaceutical composition thereof, comprising a FSP27 fragment, as shown in Table 1 in  FIG. 17 , or variants or isoforms thereof. 
     
     
         10 . The pharmaceutical composition of  claim 9  further comprising one or more FSP27 medicaments, or one or more pharmaceutically acceptable modifications of FSP27 thereof, optionally together with one or more inert carriers and/or diluents, the FSP27 medicament being present in an amount sufficient to treat one or more cardiovascular diseases. 
     
     
         11 . The composition of  claim 9 , wherein the FSP27 protein variant or isoform thereof has an amino acid sequence having greater than about 85% homology to the FSP27 sequences. 
     
     
         12 . The composition of  claim 9 , wherein the FSP27 protein variant or isoforms thereof has an amino acid sequence having greater than about 90% homology to the FSP27 sequences. 
     
     
         13 . The composition of  claim 9 , wherein the FSP27 protein variant or isoforms thereof has an amino acid sequence having greater than about 95% homology to the FSP27 sequences. 
     
     
         14 . The composition of  claim 9 , wherein the FSP27 protein variant or isoforms thereof has an amino acid sequence having greater than about 99% homology to the FSP27 sequences. 
     
     
         15 . The composition of  claim 9 , wherein the FSP27 protein is naturally occurring. 
     
     
         16 . The composition of  claim 9 , wherein the FSP27 protein is a recombinant protein. 
     
     
         17 . The composition of  claim 9 , wherein the FSP27 protein comprises a core FSP27 domain comprising one of: aa120-239; aa120-230; aa120-210; aa120-140; aa120-220; aa140-210; and/or aa173-220. 
     
     
         18 . The composition of  claim 9 , wherein the FSP27 protein is a human protein. 
     
     
         19 . The composition of  claim 9 , wherein the subject is a human. 
     
     
         20 . The composition of  claim 9 , wherein the subject experiences reduced cardiovascular disease. 
     
     
         21 . The composition of  claim 9 , wherein the nucleic acid encoding the FSP27 protein is operably linked to a promoter. 
     
     
         22 . The composition of  claim 9 , wherein the composition comprises a plasmid, the plasmid comprising the nucleic acid encoding the FSP27 protein operably linked to a promoter. 
     
     
         23 . The composition of  claim 9 , wherein the composition comprises a viral vector, the viral vector comprising the nucleic acid encoding the FSP27 protein operably linked to a promoter.